REUTERS After the Bell - BioMarin shares jump on drug trial news
NEW YORK, March 15 (Reuters) - Shares of BioMarin Pharmaceutical Inc. <BMRN.O> jumped more than 14 percent in after-hours trading on Wednesday after the company said an experimental oral molecule for the treatment of phenylketonuria (PKU) met its goals in a late-stage clinical trial.
The stock surged $1.79 to $14.24 on the Inet electronic brokerage system from a Nasdaq close of $12.45. ((Reporting by Ellis Mnyandu editing by Jonathan Oatis rm://ellis.mnyandu.reuters.com@reuters.net Telephone: + 1 646-223-6085))
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.